New drug combo aims to fight tough breast cancer
NCT ID NCT07045311
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests two different drug combinations—JS207 plus 9MW2821 or JS207 plus albumin paclitaxel—as a first treatment for people with recurrent or metastatic triple-negative breast cancer. The study will enroll 80 participants to see if these combinations can shrink tumors and control the disease. Researchers will also monitor side effects and how long the benefits last.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- JS207 combined with 9MW2821 or albumin paclitaxel
- What this could lead to
- If successful, this could offer a new first-line treatment option for people with advanced triple-negative breast cancer, potentially improving tumor shrinkage and delaying disease progression.
- What could go wrong
- This is an early Phase 2 trial with only 80 participants, so results may not apply to everyone. The combination therapies may cause side effects, and there is no guarantee they will work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2025
- Expected to finish
-
Mar 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female age 18 - 75 years old； 2. Voluntary participation in clinical study； 3. Histologically confirmed unresectable, locally advanced or metastatic triple-negative breast cancer(absence of HER2, ER, and PR expression); 4. No prior systemic antitumor therapy for locally advanced or Metastatic TNBC； 5. Prior use of systemic anti-tumor therapy in the neoadjuvant and/or adjuvant phase is allowed, but must meet the following conditions: (1) the time interval between the end of neoadjuvant/adjuvant therapy and the occurrence of recurrence/metastasis is ≥6 months; (2) Arm2: if taxane is used in the neoadjuvant/adjuvant phase, the DFI must be ≥12 months; 6. Adequate organ function; 7. ECOG performance status of 0 or 1; 8. Life expectancy 12 weeks; 9. Measurable disease, as defined by RECIST v1.1; Exclusion Criteria: 1. Untreated or active central nervous system (CNS) metastases； 2. Uncontrolled pleural effusion, pericardial effusion or ascites； 3. Tumor encasement of important vessels or significant necrosis and cavitation that may cause a risk of hemorrhage； 4. History of significant bleeding tendency or severe coagulation disorder； 5. Uncontrolled hypertension； 6. Active autoimmune diseases requiring systemic treatmen within 2 years prior to the first dose； 7. History of interstitial lung disease or previous Noninfectious pneumonitis treated with corticosteroids, or evidence of active Pneumonia in radiology on screening period； 8. Eye disorders or symptoms: severe xerophthalmia, keratoconjunctivitis sicca, severe exposure keratitis, or other conditions； 9. Severe cardiovascular disease； 10. Serious infection (CTCAE 5.0 Grade\>2) within 28 days prior to the first dose of study drug； 11. Previous treatment with anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or drugs targeting other stimulatory or co-inhibitory T cell receptors (e.g., CTLA-4, OX-40, CD137) in (new) adjuvant therapy is allowed, if DFI is ≥6 months previously treated with Antibody-Drug Conjugates conjugated with MMAE and/or targeting Nectin-4, such as Enfortumab Vedotin is not allowed； 12. History of another malignancy within 5 years before the first dose of study drug； 13. Not suitable to receive study treatment for other conditions as per investigator；
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Triple-negative breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
22 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Affiliated Hospital of Hebei University
RECRUITINGBaoding, Hebei, 071030, China
-
Affiliated Tumor Hospital of Xinjiang Medical University
RECRUITINGÜrümqi, Xinjiang Uygur Autonomous Region, 830000, China
-
Anhui Provincial Cancer Hospital
NOT_YET_RECRUITINGHefei, Anhui, 230000, China
-
Ceneral Hosipital of Ningxia Medical University
NOT_YET_RECRUITINGYinchuan, Ningxia, 750000, China
-
Guangdong women and children's hospital and health institute
NOT_YET_RECRUITINGGuangzhou, Guangdong, 511400, China
-
Harbin Medical University Affiliated Cancer Hospital
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150001, China
-
Harbin Medical University Affiliated Cancer Hospital
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150001, China
-
Henan Cancer Hospital
RECRUITINGZhangzhou, Henan, 450003, China
-
Hubei Cancer Hospital
RECRUITINGWuhan, Hubei, 430079, China
-
Jiangsu Cancer Hospital
RECRUITINGNanjing, Jiangsu, 210009, China
-
Jiangsu Province Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, 210029, China
-
Jilin University First Hospital
RECRUITINGChangchun, Jilin, 130021, China
-
Liaoning Cancer Hospital&Institute
RECRUITINGShenyang, Liaoning, 110801, China
-
Nanchang People'S Hospital
NOT_YET_RECRUITINGNanchang, Jiangxi, 330000, China
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
-
The Affiliated Hospital of Qingdao University
RECRUITINGQingdao, Shandong, 266035, China
-
The Fifth Medical Center of PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100071, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
RECRUITINGXian, Shanxi, 710061, China
-
The First Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110002, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310000, China
-
The Second Hospital of Dalian Medical University
RECRUITINGDalian, Liaoning, 116027, China
-
Xi'an International Medical Center Hospital
RECRUITINGXian, Shanxi, 710100, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to why some cancer treatments work better
- Unlocking TNBC survival: genetic clues from 3,648 women
- New drug targets Sugar-Coated proteins on cancer cells
- New antibody aims to preserve immune checkpoint while fighting cancer
- Blood test aims to track cancer treatment response in real time
- Off-the-Shelf immune cells target solid tumors